GE, ThoughtWire partner on efficiency-boosting systems for hospitals

GE

GE Healthcare and Toronto-based ThoughtWire announced a 5-year partnership to help with digital tool implementation in hospitals and health systems. The two will work together to help simplify and enable real-time decision-making using apps.

“The goal of this collaboration is to help providers deliver seamless patient care,” said Jeff Terry, managing principal at GE Healthcare.

GE has typically worked on apps at the hospital and health system level and ThoughtWire has worked in the workflow space. The partnership aims to develop tech that helps both hospitals and patients by reducing emergency room wait times, lengths of stay in hospitals and the time it takes to get back lab or radiology results, in addition to improving access to complex care.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Michael Monteith, CEO of ThoughtWire, noted the emphasis on boosting the efficiency and effectiveness of healthcare. "By combining our capabilities ThoughtWire and GE can unlock the full potential of people, data, and technology to improve the delivery of healthcare in today’s digital age,” Monteith said.

GE has been on a roll with partnerships and acquisitions in the digital health space lately, with its most recent being the acquisition of Biosafe Group. Biosafe is a supplier of integrated cell bioprocessing systems, and GE aims to develop a digitally enabled offering of tools, solutions and services for cell therapy. 

- here's the press release

Related Articles: 
GE to boost cell therapy tech with Biosafe acquisition
GE Healthcare hand-held ultrasound in pilot NHS test, $20M Nigerian health initiative
GE Healthcare, Endra partner to improve point-of-care ultrasound for fatty liver

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.